MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

NCT05299983 | Completed Results

• 1 other identifier: 140604
• Study Type: interventional
• Target: 410
• Locations: 1 country
• Sites: 1

Brief Summary

As part of a National Institute on Aging -funded R01, the investigators developed an evidence-based, multi-media digital resource entitled MyMenoPlan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. MyMenoPlan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.

Conditions

Menopause; Premenopause; Postmenopause

Keywords

Computer-Assisted Decision Making; Internet-Based Intervention

Outcome Measures

Primary Outcomes (4)

• Perceived Quality of Information

  This 7-item, 5-point Likert scale (1- Strongly disagree to 5 - Strongly agree) is adapted from the Post-Study System Usability Questionnaire (PSSUQ) in Lewis (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (perceived quality of information). Items: 1. Reading the information made me feel in more control of my perimenopause/menopause. 2. The information on the website(s) was helpful to me. 3. I found the information I was looking for. 4. The information answered my questions about perimenopause/menopause. 5. I liked the website (s). 6. I would have liked more in-depth information. (reverse-coded) 7. The website(s) were fairly comprehensive about perimenopause /menopause.

  Each survey question is answered after spending at least 20 minutes on the assigned website(s)

• Readability

  This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree)scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (readability). Items: 1. The information I read was clear. 2. The information I read was easy for me to understand.

  Each survey question is answered after spending at least 20 minutes on the assigned website(s)

• Self-Efficacy for Managing Menopause Symptoms

  This is a newly developed Likert scale (1- Strongly disagree to 5 - Strongly agree) for assessing participants' beliefs in their own abilities in managing menopausal symptoms. The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (self-efficacy). Items: 1. If I want to, I am certain I could figure out the treatments or coping strategies that would work best for me. 2. I feel I could treat or cope with my symptoms of perimenopause/menopause if I want to.

  Each survey question is answered after spending at least 20 minutes on the assigned website(s)

• Credibility

  This 2-item, 5-point Likert (1- Strongly disagree to 5 - Strongly agree) scale was derived from the Standardized User Experience Percentile Rank Questionnaire (SUPR-Q) in Sauro (1995). The range of this scale is 1-5. The items in this scale were averaged with a higher score meaning higher on this outcome (credibility). Items: 1. The information is credible. 2. The information is trustworthy.

  Each survey question is answered after spending at least 20 minutes on the assigned website(s)

Study Arms (2)

MyMenoPlan

EXPERIMENTAL

Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.

Other: MyMenoPlan

Control

ACTIVE COMPARATOR

Participants are asked to spend at least 20 minutes on at least one of the following websites or other websites of their choice: 1. North American Menopause Society: https://www.menopause.org/for-women 2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause 3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause

Other: Control

Interventions

MyMenoPlan OTHER

Participants are asked to spend at least 20 minutes on the website (MyMenoPlan) assigned to them.

MyMenoPlan

Control OTHER

Participants are asked to spend at least 20 minutes on at least one of the following websites: 1. North American Menopause Society: https://www.menopause.org/for-women 2. National Institute on Aging: https://www.nia.nih.gov/health/topics/menopause 3. The Office on Women's Health-Menopause: https://www.womenshealth.gov/menopause

Control

Eligibility Criteria

• Age: 40 Years - 60 Years
• Gender Eligibility Details: Based on self-representation of gender identity this study includes females, non-binary people and transgender men defined as follows: Non-binary: a non-binary person is someone who does not identify as exclusively a man or a woman. Transgender male: A transgender male is a man who was assigned female at birth.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• As stated above

You may not qualify if:

• N/A

Sponsors & Collaborators

• University of California, San Diego: lead

Study Sites (1)

UC San Diego

La Jolla, California, 92037, United States

Location

Related Publications (1)

• Snyder LB, Newton KM, Ng HX, Reed SD, Guthrie KA, Zambrano V, LaCroix AZ. Positive impact of a menopause website - MyMenoplan.org - on treatment intentions, knowledge, and decision making: A randomized controlled trial. Maturitas. 2025 Aug;199:108630. doi: 10.1016/j.maturitas.2025.108630. Epub 2025 Jun 5.

  PMID: 40505527 DERIVED

Results Point of Contact

• Title: Andrea LaCroix
• Organization: UC San Diego

alacroix@ucsd.edu

(858) 822-0627

Study Officials

• Andrea Z. LaCroix, PhD

  University of California, San Diego

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Distinguished Professor of Epidemiology

Study Record Dates

• First Submitted: March 1, 2022
• First Posted: March 29, 2022
• Study Start: January 15, 2022
• Primary Completion: March 31, 2022
• Study Completion: March 31, 2022
• Last Updated: March 27, 2025
• Results First Posted: March 27, 2025

Record last verified: 2025-03

Locations

US (1)